Market Cap 162.07M
Revenue (ttm) 70.39M
Net Income (ttm) -43.97M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -62.47%
Debt to Equity Ratio 1.03
Volume 608,700
Avg Vol 1,158,828
Day's Range N/A - N/A
Shares Out 109.51M
Stochastic %K 10%
Beta 2.52
Analysts Strong Sell
Price Target $6.33

Company Profile

Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 421 8100
Address:
200 Penobscot Drive, Redwood City, United States
AtariLynx
AtariLynx Sep. 16 at 2:05 PM
$CDXS at this price the best time to buy is every time you can!
0 · Reply
Fingerlickengood
Fingerlickengood Sep. 16 at 11:59 AM
$CDXS ”One particular customer is very interested in eking out potency opportunities from stereochemical control. Codexis is making material with specific stereo configurations and advancing studies to understand activity opportunities, with other companies in negotiations for similar work.” https://finance.yahoo.com/healthcare/articles/codexis-inc-cdxs-q2-2026-050235212.html
0 · Reply
Camille65
Camille65 Sep. 16 at 6:24 AM
$CDXS stock unable to even break the $1.50 fund raising price. TOO bad. The marco picture is gloomy (rising interest rate disfavour biotech particularly micro unprofitable, bonds issue plus horrible September with options expiration this coming Friday). Shorts/bears are seizing the moment. Codexis unable to make any breakthrough; same narrative with no delivery except crashing the stock. Dull presentation last week. Still a single design win and so far no signs of commercial validation. The combination is a stock spiraling southwards unless they pull a rabbit comes out of the hat!
0 · Reply
djohndjohn
djohndjohn Sep. 15 at 9:06 PM
$CDXS worthless stock worthless management. Can’t seem to sell ECO.
0 · Reply
Camille65
Camille65 Sep. 12 at 11:57 AM
$CDXS The Cantor Presentation was entirely about the ECO, almost nothing about the enzyme segment which is generating revenues. Nothing about the recent drugs approval and their due milestone payments and related supply deals, given their potential blockbuster market. Alison is a scientist and took her time for “technical” ECO benefits. It seems they are again pushing back on commercial validation milestones, just check their September presentation no more mention of licensing deals with either CDMO or pharmaceutical. ECO sounds like “pipedream” with so far, single design win of 50g siRNA. The forthcoming meeting with FDA does not necessarily translate into approval which it seems may drag to 2027. Alison reply to the last question about investors perception and “undervaluation” was subdued. No wonder she never purchased any single share. In summary, unless (or until) surprise development show up “soon”, the stock likely to keep underperforming and languishing in "value" territories.
3 · Reply
Fingerlickengood
Fingerlickengood Sep. 11 at 10:53 AM
$CDXS @Emperortikki As Allison Moore said in yesterdays presentation, industry will need to invest $1B to buildout a facility to manufacture 1-metric ton of any given siRNA product using current technology. Additionally, she pointed out that there is currently not enough Acetonitrile on the planet, which will be needed, to manufacture all the anticipated siRNA drugs coming to market w/in the next few years that will be in global demand annually. If you go back and look at the scaling of Inclisiran, the only limit to scaling is the number of reactors they are currently running in their small proof of concept facility. Once they have the new larger facility up and running they will have many reactors and thus produciton scalling will be multiplied by the number of reactors they install and only limited on square footage of the facility itself. If you don't agree, it's only of a matter of time before it's proven and that will happen by the end of 2027! https://www.bachem.com/knowledge-center/webinar-efficient-large-scale-sirna-manufacturing-enzymatic-ligation-of-short-rna-fragments/
3 · Reply
djohndjohn
djohndjohn Sep. 11 at 8:40 AM
$CDXS https://m.investing.com/news/transcripts/codexis-at-cantor-conference-enzymatic-rna-manufacturing-gains-ground-93CH-4896298?ampMode=1
1 · Reply
Emperortikki
Emperortikki Sep. 11 at 4:12 AM
$CDXS updated presentation on IR website Goals for the rest of 2026 (start placing your bets). If the partnership is actually announced, the longs will be in a much better position. • Progress from 100-500g pilot scale production of siRNA in ECO Innovation Lab • Expand a CDMO scale-up partnership for ECO Synthesis • Secure ECO Synthesis raw materials supply chain • Maintain pharma biocatalysis business at healthy gross margins
0 · Reply
Fingerlickengood
Fingerlickengood Sep. 10 at 3:01 PM
$CDXS www.investing.com/news/transcripts/codexis-at-cantor-conference-enzymatic-rna-manufacturing-gains-ground-93CH-4896298 Key Takeaways The company estimated that its approach is about 70% more capital efficient than conventional methods and uses an aqueous process with far less solvent waste. Codexis said it is routinely making 100 grams in its innovation lab with kilo-scale operations planned for end-2027. The company said it has been accepted into the FDA Emerging Technology Program and has an upcoming meeting with FDA staff to discuss product specifications, stereochemical control and starting material classification. Management pointed to a growing siRNA market, with 8 approved therapies, an estimated 400 to 600 assets in development and more than 100 in FDA clinical trials.
1 · Reply
Fingerlickengood
Fingerlickengood Sep. 10 at 2:39 PM
0 · Reply
Latest News on CDXS
Codexis Slides: Corporate presentation

Sep 10, 2026, 7:00 AM EDT - 6 days ago

Codexis Slides: Corporate presentation


Codexis reports Q2 EPS (13c), consensus (12c)

2026-08-17T11:13:06.000Z - 4 weeks ago

Codexis reports Q2 EPS (13c), consensus (12c)


Codexis backs FY26 revenue view $72M-$76M, consensus $74.1M

2026-08-17T11:12:49.000Z - 4 weeks ago

Codexis backs FY26 revenue view $72M-$76M, consensus $74.1M


Codexis price target lowered to $8 from $9 at Piper Sandler

2026-08-17T11:06:13.000Z - 4 weeks ago

Codexis price target lowered to $8 from $9 at Piper Sandler


Codexis Earnings Call Transcript: Q2 2026

Aug 11, 2026, 4:30 PM EDT - 5 weeks ago

Codexis Earnings Call Transcript: Q2 2026


Codexis Quarterly report: Q2 2026

Aug 11, 2026, 4:30 PM EDT - 5 weeks ago

Codexis Quarterly report: Q2 2026


Codexis Earnings release: Q2 2026

Aug 11, 2026, 4:30 PM EDT - 5 weeks ago

Codexis Earnings release: Q2 2026


Codexis Reports Second Quarter 2026 Financial Results

Aug 11, 2026, 4:05 PM EDT - 5 weeks ago

Codexis Reports Second Quarter 2026 Financial Results


Codexis 16.667M share Spot Secondary priced at $1.50

2026-07-24T11:25:13.000Z - 7 weeks ago

Codexis 16.667M share Spot Secondary priced at $1.50


Codexis Announces Pricing of Public Offering of Common Stock

Jul 23, 2026, 11:47 PM EDT - 7 weeks ago

Codexis Announces Pricing of Public Offering of Common Stock


Codexis announces common stock offering, no amount given

2026-07-23T20:26:01.000Z - 7 weeks ago

Codexis announces common stock offering, no amount given


Codexis Announces Proposed Public Offering of Common Stock

Jul 23, 2026, 4:13 PM EDT - 7 weeks ago

Codexis Announces Proposed Public Offering of Common Stock


Codexis Transcript: AGM 2026

Jun 17, 2026, 12:00 PM EDT - 3 months ago

Codexis Transcript: AGM 2026


Codexis Slides: Corporate presentation

Jun 2, 2026, 7:00 AM EDT - 3 months ago

Codexis Slides: Corporate presentation


Codexis reports Q1 EPS (10c), consensus (10c)

2026-05-07T22:52:18.000Z - 4 months ago

Codexis reports Q1 EPS (10c), consensus (10c)


Codexis backs FY26 revenue view $72M-$76M, consensus $74.24M

2026-05-07T22:51:14.000Z - 4 months ago

Codexis backs FY26 revenue view $72M-$76M, consensus $74.24M


Codexis Earnings Call Transcript: Q1 2026

May 7, 2026, 4:30 PM EDT - 4 months ago

Codexis Earnings Call Transcript: Q1 2026


Codexis Earnings release: Q1 2026

May 7, 2026, 4:30 PM EDT - 4 months ago

Codexis Earnings release: Q1 2026


Codexis Quarterly report: Q1 2026

May 7, 2026, 4:30 PM EDT - 4 months ago

Codexis Quarterly report: Q1 2026


Codexis Reports First Quarter 2026 Financial Results

May 7, 2026, 4:05 PM EDT - 4 months ago

Codexis Reports First Quarter 2026 Financial Results


Codexis to share RNA manufacturing advances at TIDES USA

Apr 29, 2026, 9:00 AM EDT - 4 months ago

Codexis to share RNA manufacturing advances at TIDES USA


Codexis Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Codexis Proxy statement: Proxy filing


Codexis Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Codexis Proxy statement: Proxy filing


Codexis Earnings Call Transcript: Q4 2025

Mar 11, 2026, 4:30 PM EDT - 6 months ago

Codexis Earnings Call Transcript: Q4 2025


Codexis Annual report: Q4 2025

Mar 11, 2026, 4:30 PM EDT - 6 months ago

Codexis Annual report: Q4 2025


Codexis Earnings release: Q4 2025

Mar 11, 2026, 4:30 PM EDT - 6 months ago

Codexis Earnings release: Q4 2025


Codexis reports Q4 EPS 11c, consensus (4c)

2026-03-11T20:25:25.000Z - 6 months ago

Codexis reports Q4 EPS 11c, consensus (4c)


Codexis sees FY26 revenue $72M-$76M, consensus $70.8M

2026-03-11T20:25:07.000Z - 6 months ago

Codexis sees FY26 revenue $72M-$76M, consensus $70.8M


Codexis announces agreement to manufacture 50 g siRNA

2026-03-04T15:11:46.000Z - 6 months ago

Codexis announces agreement to manufacture 50 g siRNA


Codexis Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 11:50 AM EST - 6 months ago

Codexis Transcript: TD Cowen 46th Annual Health Care Conference


Codexis achieves ISO 9001:2015 certification

2026-02-10T14:05:57.000Z - 7 months ago

Codexis achieves ISO 9001:2015 certification


Codexis Achieves ISO 9001:2015 Certification

Feb 10, 2026, 9:00 AM EST - 7 months ago

Codexis Achieves ISO 9001:2015 Certification


Codexis signs evaluation agreement with Axolabs

2026-01-07T14:12:08.000Z - 8 months ago

Codexis signs evaluation agreement with Axolabs


Codexis Announces Signing of Lease for GMP Manufacturing Facility

Nov 10, 2025, 9:00 AM EST - 10 months ago

Codexis Announces Signing of Lease for GMP Manufacturing Facility


Codexis reports Q3 EPS (22c), consensus (13c)

2025-11-06T22:35:34.000Z - 10 months ago

Codexis reports Q3 EPS (22c), consensus (13c)


Codexis Earnings Call Transcript: Q3 2025

Nov 6, 2025, 4:30 PM EST - 10 months ago

Codexis Earnings Call Transcript: Q3 2025


Codexis Quarterly report: Q3 2025

Nov 6, 2025, 4:30 PM EST - 10 months ago

Codexis Quarterly report: Q3 2025


Codexis Earnings release: Q3 2025

Nov 6, 2025, 4:30 PM EST - 10 months ago

Codexis Earnings release: Q3 2025


Codexis Slides: Q3 2025

Nov 6, 2025, 4:30 PM EST - 10 months ago

Codexis Slides: Q3 2025


Codexis, Nitto Denko Avecia enter evaluation agreement

2025-10-29T14:05:32.000Z - 10 months ago

Codexis, Nitto Denko Avecia enter evaluation agreement


Codexis Transcript: Cantor Global Healthcare Conference 2025

Sep 4, 2025, 3:55 PM EDT - 1 year ago

Codexis Transcript: Cantor Global Healthcare Conference 2025


Codexis to Participate in Cantor Global Healthcare Conference

Aug 28, 2025, 9:00 AM EDT - 1 year ago

Codexis to Participate in Cantor Global Healthcare Conference


Codexis Earnings Call Transcript: Q2 2025

Aug 13, 2025, 4:30 PM EDT - 1 year ago

Codexis Earnings Call Transcript: Q2 2025


Codexis Quarterly report: Q2 2025

Aug 13, 2025, 4:30 PM EDT - 1 year ago

Codexis Quarterly report: Q2 2025


Codexis Earnings release: Q2 2025

Aug 13, 2025, 4:30 PM EDT - 1 year ago

Codexis Earnings release: Q2 2025


Codexis Slides: Q2 2025

Aug 13, 2025, 4:30 PM EDT - 1 year ago

Codexis Slides: Q2 2025


Codexis Reports Second Quarter 2025 Financial Results

Aug 13, 2025, 4:05 PM EDT - 1 year ago

Codexis Reports Second Quarter 2025 Financial Results


Codexis Transcript: Status Update

May 22, 2025, 8:00 AM EDT - 1 year ago

Codexis Transcript: Status Update


Codexis Press release: Status Update

May 22, 2025, 8:00 AM EDT - 1 year ago

Codexis Press release: Status Update


Codexis Earnings Call Transcript: Q1 2025

May 14, 2025, 4:30 PM EDT - 1 year ago

Codexis Earnings Call Transcript: Q1 2025


Codexis Quarterly report: Q1 2025

May 14, 2025, 4:30 PM EDT - 1 year ago

Codexis Quarterly report: Q1 2025


Codexis Earnings release: Q1 2025

May 14, 2025, 4:30 PM EDT - 1 year ago

Codexis Earnings release: Q1 2025


Codexis Slides: Q1 2025

May 14, 2025, 4:30 PM EDT - 1 year ago

Codexis Slides: Q1 2025


Codexis reports Q1 EPS (25c), consensus (21c)

2025-05-14T20:16:47.000Z - 1 year ago

Codexis reports Q1 EPS (25c), consensus (21c)


Codexis sees FY25 revenue $64M-$68M, consensus $65.67M

2025-05-14T20:16:39.000Z - 1 year ago

Codexis sees FY25 revenue $64M-$68M, consensus $65.67M


Codexis Reports First Quarter 2025 Financial Results

May 14, 2025, 4:05 PM EDT - 1 year ago

Codexis Reports First Quarter 2025 Financial Results


Codexis Proxy statement: Proxy Filing

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Codexis Proxy statement: Proxy Filing


Codexis Proxy statement: Proxy Filing

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Codexis Proxy statement: Proxy Filing


Codexis appoints Cynthia Collins to board of directors

2025-04-01T11:21:28.000Z - 1 year ago

Codexis appoints Cynthia Collins to board of directors


Codexis Announces New Employment Inducement Grants

Mar 7, 2025, 4:05 PM EST - 1 year ago

Codexis Announces New Employment Inducement Grants


Codexis Earnings Call Transcript: Q4 2024

Feb 27, 2025, 4:30 PM EST - 1 year ago

Codexis Earnings Call Transcript: Q4 2024


Codexis Annual report: Q4 2024

Feb 27, 2025, 4:30 PM EST - 1 year ago

Codexis Annual report: Q4 2024


Codexis Earnings release: Q4 2024

Feb 27, 2025, 4:30 PM EST - 1 year ago

Codexis Earnings release: Q4 2024


Codexis Slides: Q4 2024

Feb 27, 2025, 4:30 PM EST - 1 year ago

Codexis Slides: Q4 2024


Codexis Appoints Christos Richards to Board of Directors

Jan 16, 2025, 4:05 PM EST - 1 year ago

Codexis Appoints Christos Richards to Board of Directors


Codexis Transcript: Stifel 2024 Healthcare Conference

Nov 18, 2024, 2:25 PM EST - 1 year ago

Codexis Transcript: Stifel 2024 Healthcare Conference


Codexis Transcript: Status Update

Nov 14, 2024, 4:30 PM EST - 1 year ago

Codexis Transcript: Status Update


Codexis Press release: Status Update

Nov 14, 2024, 4:30 PM EST - 1 year ago

Codexis Press release: Status Update


Codexis to Participate in Upcoming Healthcare Conferences

Nov 4, 2024, 4:05 PM EST - 1 year ago

Codexis to Participate in Upcoming Healthcare Conferences


Codexis Earnings Call Transcript: Q3 2024

Oct 31, 2024, 4:30 PM EDT - 1 year ago

Codexis Earnings Call Transcript: Q3 2024


Codexis Quarterly report: Q3 2024

Oct 31, 2024, 4:30 PM EDT - 1 year ago

Codexis Quarterly report: Q3 2024


Codexis Earnings release: Q3 2024

Oct 31, 2024, 4:30 PM EDT - 1 year ago

Codexis Earnings release: Q3 2024


Codexis Slides: Q3 2024

Oct 31, 2024, 4:30 PM EDT - 1 year ago

Codexis Slides: Q3 2024


Codexis Publishes FY2023 Sustainability Disclosures

Aug 15, 2024, 4:05 PM EDT - 2 years ago

Codexis Publishes FY2023 Sustainability Disclosures


Codexis Earnings Call Transcript: Q2 2024

Aug 8, 2024, 4:30 PM EDT - 2 years ago

Codexis Earnings Call Transcript: Q2 2024


Codexis Quarterly report: Q2 2024

Aug 8, 2024, 4:30 PM EDT - 2 years ago

Codexis Quarterly report: Q2 2024


Codexis Earnings release: Q2 2024

Aug 8, 2024, 4:30 PM EDT - 2 years ago

Codexis Earnings release: Q2 2024


Codexis Slides: Q2 2024

Aug 8, 2024, 4:30 PM EDT - 2 years ago

Codexis Slides: Q2 2024


Codexis Transcript: Jefferies Global Healthcare Conference

Jun 5, 2024, 11:30 AM EDT - 2 years ago

Codexis Transcript: Jefferies Global Healthcare Conference


Codexis Earnings Call Transcript: Q1 2024

May 2, 2024, 4:30 PM EDT - 2 years ago

Codexis Earnings Call Transcript: Q1 2024


Codexis Quarterly report: Q1 2024

May 2, 2024, 4:30 PM EDT - 2 years ago

Codexis Quarterly report: Q1 2024


Codexis Earnings release: Q1 2024

May 2, 2024, 4:30 PM EDT - 2 years ago

Codexis Earnings release: Q1 2024


Codexis Slides: Q1 2024

May 2, 2024, 4:30 PM EDT - 2 years ago

Codexis Slides: Q1 2024


Codexis Registration statement: Registration Filing

May 2, 2024, 8:00 AM EDT - 2 years ago

Codexis Registration statement: Registration Filing


Codexis Proxy statement: Proxy Filing

Apr 25, 2024, 8:00 AM EDT - 2 years ago

Codexis Proxy statement: Proxy Filing


Codexis Proxy statement: Proxy Filing

Apr 25, 2024, 8:00 AM EDT - 2 years ago

Codexis Proxy statement: Proxy Filing


Codexis to Report First Quarter 2024 Financial Results on May 2

Apr 18, 2024, 4:05 PM EDT - 2 years ago

Codexis to Report First Quarter 2024 Financial Results on May 2


Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board

Apr 11, 2024, 7:05 AM EDT - 2 years ago

Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board


Codexis Earnings Call Transcript: Q4 2023

Feb 28, 2024, 4:30 PM EST - 2 years ago

Codexis Earnings Call Transcript: Q4 2023


Codexis Annual report: Q4 2023

Feb 28, 2024, 4:30 PM EST - 2 years ago

Codexis Annual report: Q4 2023


Codexis Earnings release: Q4 2023

Feb 28, 2024, 4:30 PM EST - 2 years ago

Codexis Earnings release: Q4 2023


Codexis Slides: Q4 2023

Feb 28, 2024, 4:30 PM EST - 2 years ago

Codexis Slides: Q4 2023


AtariLynx
AtariLynx Sep. 16 at 2:05 PM
$CDXS at this price the best time to buy is every time you can!
0 · Reply
Fingerlickengood
Fingerlickengood Sep. 16 at 11:59 AM
$CDXS ”One particular customer is very interested in eking out potency opportunities from stereochemical control. Codexis is making material with specific stereo configurations and advancing studies to understand activity opportunities, with other companies in negotiations for similar work.” https://finance.yahoo.com/healthcare/articles/codexis-inc-cdxs-q2-2026-050235212.html
0 · Reply
Camille65
Camille65 Sep. 16 at 6:24 AM
$CDXS stock unable to even break the $1.50 fund raising price. TOO bad. The marco picture is gloomy (rising interest rate disfavour biotech particularly micro unprofitable, bonds issue plus horrible September with options expiration this coming Friday). Shorts/bears are seizing the moment. Codexis unable to make any breakthrough; same narrative with no delivery except crashing the stock. Dull presentation last week. Still a single design win and so far no signs of commercial validation. The combination is a stock spiraling southwards unless they pull a rabbit comes out of the hat!
0 · Reply
djohndjohn
djohndjohn Sep. 15 at 9:06 PM
$CDXS worthless stock worthless management. Can’t seem to sell ECO.
0 · Reply
Camille65
Camille65 Sep. 12 at 11:57 AM
$CDXS The Cantor Presentation was entirely about the ECO, almost nothing about the enzyme segment which is generating revenues. Nothing about the recent drugs approval and their due milestone payments and related supply deals, given their potential blockbuster market. Alison is a scientist and took her time for “technical” ECO benefits. It seems they are again pushing back on commercial validation milestones, just check their September presentation no more mention of licensing deals with either CDMO or pharmaceutical. ECO sounds like “pipedream” with so far, single design win of 50g siRNA. The forthcoming meeting with FDA does not necessarily translate into approval which it seems may drag to 2027. Alison reply to the last question about investors perception and “undervaluation” was subdued. No wonder she never purchased any single share. In summary, unless (or until) surprise development show up “soon”, the stock likely to keep underperforming and languishing in "value" territories.
3 · Reply
Fingerlickengood
Fingerlickengood Sep. 11 at 10:53 AM
$CDXS @Emperortikki As Allison Moore said in yesterdays presentation, industry will need to invest $1B to buildout a facility to manufacture 1-metric ton of any given siRNA product using current technology. Additionally, she pointed out that there is currently not enough Acetonitrile on the planet, which will be needed, to manufacture all the anticipated siRNA drugs coming to market w/in the next few years that will be in global demand annually. If you go back and look at the scaling of Inclisiran, the only limit to scaling is the number of reactors they are currently running in their small proof of concept facility. Once they have the new larger facility up and running they will have many reactors and thus produciton scalling will be multiplied by the number of reactors they install and only limited on square footage of the facility itself. If you don't agree, it's only of a matter of time before it's proven and that will happen by the end of 2027! https://www.bachem.com/knowledge-center/webinar-efficient-large-scale-sirna-manufacturing-enzymatic-ligation-of-short-rna-fragments/
3 · Reply
djohndjohn
djohndjohn Sep. 11 at 8:40 AM
$CDXS https://m.investing.com/news/transcripts/codexis-at-cantor-conference-enzymatic-rna-manufacturing-gains-ground-93CH-4896298?ampMode=1
1 · Reply
Emperortikki
Emperortikki Sep. 11 at 4:12 AM
$CDXS updated presentation on IR website Goals for the rest of 2026 (start placing your bets). If the partnership is actually announced, the longs will be in a much better position. • Progress from 100-500g pilot scale production of siRNA in ECO Innovation Lab • Expand a CDMO scale-up partnership for ECO Synthesis • Secure ECO Synthesis raw materials supply chain • Maintain pharma biocatalysis business at healthy gross margins
0 · Reply
Fingerlickengood
Fingerlickengood Sep. 10 at 3:01 PM
$CDXS www.investing.com/news/transcripts/codexis-at-cantor-conference-enzymatic-rna-manufacturing-gains-ground-93CH-4896298 Key Takeaways The company estimated that its approach is about 70% more capital efficient than conventional methods and uses an aqueous process with far less solvent waste. Codexis said it is routinely making 100 grams in its innovation lab with kilo-scale operations planned for end-2027. The company said it has been accepted into the FDA Emerging Technology Program and has an upcoming meeting with FDA staff to discuss product specifications, stereochemical control and starting material classification. Management pointed to a growing siRNA market, with 8 approved therapies, an estimated 400 to 600 assets in development and more than 100 in FDA clinical trials.
1 · Reply
Fingerlickengood
Fingerlickengood Sep. 10 at 2:39 PM
0 · Reply
Fingerlickengood
Fingerlickengood Sep. 10 at 2:29 PM
$CDXS $MRK Inclisiran mentioned multiple times, as ”an example”, without directly saying something she was intentionally suggesting something! i’ve said it before and will say it again, this will very likely be their breakout contract!
1 · Reply
Fingerlickengood
Fingerlickengood Sep. 10 at 2:17 PM
$CDXS Meeting with the FDA Emerging Technologies Team in the next couple weeks!
1 · Reply
Emperortikki
Emperortikki Sep. 10 at 2:17 PM
$CDXS ummm. Ummmm ummmmmm ummmmm ummmmm. Alison ummmm can’t ummmm present. That’s what I got out of it. Ummmmm. And they don’t expect to be able to scale production until end of 2027.
3 · Reply
djohndjohn
djohndjohn Sep. 9 at 9:29 PM
$CDXS Well will Ms. Moore open her mouth tomorrow and tell us what's going on with the company? Or will she just continue to say this is what ECO can do, this is what ECO can do, this is what ECO can do Please buy our stock and trust me ECO can do this!!!! No Ms Moore tell us what you are doing with ECO and who your doing it with and how much revenue will this create?????? This is gettting sickining :)
2 · Reply
Fingerlickengood
Fingerlickengood Sep. 9 at 5:27 PM
$CDXS https://www.loopnet.com/Listing/30831-Huntwood-Ave-Hayward-CA/29050857/
0 · Reply
Fingerlickengood
Fingerlickengood Sep. 9 at 5:26 PM
$CDXS So according to the Hayward AUP support website: https://www.hayward-ca.gov/services/permits/administrative-use-permit-aup So the way I read it, it would be exempt from a AUP since it was previously zoned and permitted as a GMP facility!
1 · Reply
Fingerlickengood
Fingerlickengood Sep. 9 at 5:03 PM
$CDXS https://seekingalpha.com/news/4631179-codexis-outlines-72m-76m-2026-revenue-as-it-plans-25m-gmp-facility-build-out
1 · Reply
Fingerlickengood
Fingerlickengood Sep. 9 at 4:42 PM
$CDXS they signed the lease in November! 😂
0 · Reply
Fingerlickengood
Fingerlickengood Sep. 9 at 4:26 PM
$CDXS lol! okay you got me! 😆https://ir.codexis.com/news-events/press-releases/detail/436/codexis-announces-signing-of-lease-for-gmp-manufacturing-facility
0 · Reply
Valueforall
Valueforall Sep. 9 at 2:47 PM
$CDXS buy this 💩 big and now. Dd done. Deploy when possible status
0 · Reply
Fingerlickengood
Fingerlickengood Sep. 9 at 2:30 PM
$CDXS “a company often puts a hold on an expansion project if a buyout offer is on the table.”
3 · Reply
Emperortikki
Emperortikki Sep. 9 at 9:35 AM
$CDXS Building Permit from public records in Hayward. Status: On Hold Start Commenting with all the conspiracy theories.
2 · Reply